Carlsmed Raises Full-Year Guidance on Strong Q2 Growth
Event summary
- Q2 2026 revenue of $18.9M, up 57% YoY
- Full-year guidance raised to $74M–$78M from prior $72M–$77M
- Trained surgeon user base grew over 60% YoY
- CMS ruling effective October 1, 2026 enhances reimbursement for aprevo® lumbar procedures
The big picture
Carlsmed’s strong Q2 performance reflects growing adoption of its AI-enabled spine surgery solutions, particularly among early-career surgeons. The CMS reimbursement ruling positions the company for further expansion in a competitive medical technology landscape where scalability and surgeon training are key differentiators.
What we're watching
- Reimbursement Impact
- How the CMS ruling will affect Medicare patient access and procedure volume.
- Scalability Challenges
- Whether Carlsmed’s digital production system can sustain growth ahead of demand.
- Path to Profitability
- The pace at which operating expenses will scale relative to revenue growth.
Related topics